THOUSAND OAKS, Calif.,
Dec. 6, 2017 /PRNewswire/
-- Amgen (NASDAQ:AMGN) will host a webcast call for the
investment community at the 59th American Society of
Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m.
ET. David M. Reese, M.D., senior vice president of
Translational Sciences and Oncology at Amgen, together with other
members of Amgen's management team and a clinical investigator,
will participate to discuss the Company's oncology program,
including our BiTE® immunotherapy platform.
Live audio of the investor call will be simultaneously broadcast
over the Internet and will be available to members of the news
media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(Media)
Kristen Neese, 805-313-8267
(Media)
Arvind Sood, 805-447-1060
(Investors)
View original content with
multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-ash-2017-300567781.html
SOURCE Amgen